Loading...
DIVISLAB logo

Divi's Laboratories LimitedNSEI:DIVISLAB Stock Report

Market Cap ₹1.7t
Share Price
₹6.54k
My Fair Value
n/a
1Y12.5%
7D-3.9%
Portfolio Value
​
View

Divi's Laboratories Limited

NSEI:DIVISLAB Stock Report

Market Cap: ₹1.7t

Divi's Laboratories (DIVISLAB) Stock Overview

Engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. More details

DIVISLAB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance3/6
Financial Health5/6
Dividends4/6

Rewards

Earnings are forecast to grow 18.2% per year

Earnings grew by 35.3% over the past year

Risk Analysis

High level of non-cash earnings

Dividend of 0.46% is not well covered by free cash flows


DIVISLAB Community Fair Values

Create Narrative

See what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.

DIVISLAB logo
Divi's Laboratories

Custom Synthesis And Green Chemistry Will Harness Rising Pharmaceutical Demand

Key Takeaways Capacity expansion and GMP space optimization are enabling rapid growth in high-value custom synthesis, positioning Divi's for accelerated revenue and margin gains. Leadership in peptides, strong integration, and sustainability practices create lasting competitive advantages, making Divi's a top beneficiary of growing global demand for advanced therapies.
View narrative
₹7.75k
FV
15.6% undervalued intrinsic discount
21.87%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
DIVISLAB logo
Divi's Laboratories

Custom Synthesis And Capacity Expansion Will Unlock Global Demand

Key Takeaways Expansion in custom synthesis, technology investments, and new capacity boosts growth prospects, margin expansion, and strengthens position in complex pharma outsourcing. Enhanced backward integration, supply chain resilience, and sustainability focus reinforce Divi's competitive advantage and ensure greater client loyalty and stable long-term revenue.
View narrative
₹6.43k
FV
1.7% overvalued intrinsic discount
16.50%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
DIVISLAB logo
Divi's Laboratories

Rising Protectionism And Regulatory Burdens Will Undermine Pharma Exports

Key Takeaways Growing geopolitical protectionism, ESG scrutiny, and market shifts threaten Divi's export-led revenue model and increase compliance and operating cost pressures. Concentration risk, lasting generics pricing pressure, and slow adaptation to biologics may shrink market share, margins, and reliability of future earnings.
View narrative
₹4.76k
FV
37.5% overvalued intrinsic discount
13.55%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
View Stock Community

Divi's Laboratories Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Divi's Laboratories
Historical stock prices
Current Share Price₹6,539.50
52 Week High₹7,071.50
52 Week Low₹4,955.00
Beta0.14
1 Month Change1.00%
3 Month Change7.20%
1 Year Change12.54%
3 Year Change96.58%
5 Year Change90.82%
Change since IPO74,107.09%

Recent News & Updates

Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk

Sep 06
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk

Recent updates

Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk

Sep 06
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk

Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 10
Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation

Aug 05
Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation

Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results

Jul 17
Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results

Divi's Laboratories Limited (NSE:DIVISLAB) Investors Are Less Pessimistic Than Expected

Apr 10
Divi's Laboratories Limited (NSE:DIVISLAB) Investors Are Less Pessimistic Than Expected

Divi's Laboratories Limited's (NSE:DIVISLAB) Shareholders Might Be Looking For Exit

Dec 25
Divi's Laboratories Limited's (NSE:DIVISLAB) Shareholders Might Be Looking For Exit
User avatar

Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability

Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.

Shareholder Returns

DIVISLABIN Life SciencesIN Market
7D-3.9%-4.0%-0.4%
1Y12.5%1.4%2.8%

Return vs Industry: DIVISLAB exceeded the Indian Life Sciences industry which returned 1.6% over the past year.

Return vs Market: DIVISLAB exceeded the Indian Market which returned 1.3% over the past year.

Price Volatility

Is DIVISLAB's price volatile compared to industry and market?
DIVISLAB volatility
DIVISLAB Average Weekly Movement3.4%
Life Sciences Industry Average Movement4.9%
Market Average Movement5.1%
10% most volatile stocks in IN Market8.5%
10% least volatile stocks in IN Market3.1%

Stable Share Price: DIVISLAB has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: DIVISLAB's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199010,542Kiran Diviwww.divislabs.com

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products.

Divi's Laboratories Limited Fundamentals Summary

How do Divi's Laboratories's earnings and revenue compare to its market cap?
DIVISLAB fundamental statistics
Market cap₹1.74t
Earnings (TTM)₹24.85b
Revenue (TTM)₹100.29b
69.9x
P/E Ratio
17.3x
P/S Ratio

Is DIVISLAB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DIVISLAB income statement (TTM)
Revenue₹100.29b
Cost of Revenue₹39.32b
Gross Profit₹60.97b
Other Expenses₹36.12b
Earnings₹24.85b

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)93.61
Gross Margin60.79%
Net Profit Margin24.78%
Debt/Equity Ratio0.6%

How did DIVISLAB perform over the long term?

See historical performance and comparison

Dividends

0.5%
Current Dividend Yield
36%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/11 09:17
End of Day Share Price 2025/11/11 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Divi's Laboratories Limited is covered by 51 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
Prashant NairAmbit Capital
Ashwin MehtaAmbit Capital